Aviva PLC Raises Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Aviva PLC raised its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 103.7% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 122,774 shares of the medical equipment provider's stock after acquiring an additional 62,507 shares during the quarter. Aviva PLC owned approximately 0.06% of Zimmer Biomet worth $12,969,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the company. Franklin Resources Inc. raised its holdings in Zimmer Biomet by 398.7% in the fourth quarter. Franklin Resources Inc. now owns 3,497,764 shares of the medical equipment provider's stock worth $369,469,000 after purchasing an additional 2,796,372 shares in the last quarter. Norges Bank purchased a new stake in Zimmer Biomet in the fourth quarter worth about $216,223,000. Sound Shore Management Inc. CT bought a new position in shares of Zimmer Biomet during the fourth quarter valued at approximately $81,447,000. Equity Investment Corp grew its stake in shares of Zimmer Biomet by 57.2% in the 4th quarter. Equity Investment Corp now owns 1,021,062 shares of the medical equipment provider's stock worth $107,855,000 after buying an additional 371,653 shares during the last quarter. Finally, Van ECK Associates Corp increased its position in Zimmer Biomet by 5.9% during the 4th quarter. Van ECK Associates Corp now owns 3,955,449 shares of the medical equipment provider's stock valued at $417,814,000 after buying an additional 218,688 shares in the last quarter. Hedge funds and other institutional investors own 88.89% of the company's stock.

Remove Ads

Zimmer Biomet Stock Performance

Shares of NYSE:ZBH traded up $0.04 during midday trading on Friday, hitting $102.30. The company had a trading volume of 2,275,065 shares, compared to its average volume of 1,631,435. The company has a market cap of $20.36 billion, a price-to-earnings ratio of 22.99, a PEG ratio of 1.95 and a beta of 0.84. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.91 and a quick ratio of 0.99. The company has a fifty day moving average of $106.31 and a two-hundred day moving average of $107.03. Zimmer Biomet Holdings, Inc. has a 12-month low of $97.69 and a 12-month high of $127.32.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last issued its quarterly earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, topping analysts' consensus estimates of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same period in the previous year, the business earned $2.20 earnings per share. On average, equities research analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be given a $0.24 dividend. The ex-dividend date is Monday, March 31st. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.94%. Zimmer Biomet's payout ratio is currently 21.57%.

Insider Transactions at Zimmer Biomet

In related news, SVP Lori Winkler sold 1,443 shares of the stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total transaction of $150,649.20. Following the completion of the sale, the senior vice president now owns 8,768 shares in the company, valued at approximately $915,379.20. This trade represents a 14.13 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.95% of the company's stock.

Analyst Ratings Changes

ZBH has been the topic of a number of recent research reports. Needham & Company LLC reissued a "hold" rating on shares of Zimmer Biomet in a research note on Friday, February 7th. JMP Securities reissued a "market outperform" rating and set a $140.00 price objective on shares of Zimmer Biomet in a research report on Friday, February 7th. Raymond James decreased their target price on shares of Zimmer Biomet from $126.00 to $119.00 and set an "outperform" rating for the company in a report on Friday, February 7th. Truist Financial reiterated a "hold" rating and set a $113.00 price target (down previously from $118.00) on shares of Zimmer Biomet in a report on Monday, February 10th. Finally, Stifel Nicolaus boosted their price objective on shares of Zimmer Biomet from $130.00 to $138.00 and gave the stock a "buy" rating in a report on Thursday, January 23rd. Two analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average target price of $124.15.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.